Navigation Links
The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Date:3/13/2008

Future Generation Treatment from Abbott Shows No Thrombosis, Low MACE Rates

Out to One Year in Preliminary Clinical Study of Thirty Patients

ABBOTT PARK, Ill., March 13 /PRNewswire-FirstCall/ -- Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (retreatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year. These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007 (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0529.htm ). Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.

"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."

At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the o
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. The Lancet Publishes Vasogens ACCLAIM Results
3. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
4. Consortium publishes Phase II map of human genetic variation
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
7. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. NPS Pharmaceuticals Reports 2007 Financial Results
10. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... have succeeded in measuring vibrational motion of a single ... how vibration of a single molecule differs from the ... was performed at the University of California, Irvine, where ... works as a visiting fellow under professor Vartkess A. ... team was lead by Professor Eric O. Potma. The ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 19, 2014 Cellgen Diagnostics ... $200,000 to fund a corporate lab for its ... This development is a critical component in the ... to the implementation of personalized medicine – a ... medicine. , Indiegogo contributions will support Cellgen’s intent ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... Calif., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a ... in the areas of women,s health and cancer, today announced,that ... at the 4th,Annual BIO Investor Forum. The presentation will ... the Palace Hotel in San Francisco, CA. A live ...
... Cerimon,Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon,s ... 2007 BIO Investor Forum on,Thursday, October 11, 2007, ... in San,Francisco. The presentation will take place in ... Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company ...
... Coalition for a,Competitive Pharmaceutical Market (CCPM) issued the ... announcement regarding its,"Generic Initiative for Value and Efficiency" ... grappling with,how to manage escalating prescription drug costs, ... focus on ways to enhance timely generic access.,Today,s ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... of the world, leprosy and tuberculosis live side-by-side. ... leprosy per year, with nearly all of them ... century-old vaccine Bacille Calmette-Guerin, or BCG, provides only ... a more potent vaccine is needed to combat ... stronger weapon against both diseases., In a study ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2
... century, scientists have struggled with plutonium contamination spreading further ... in humans and animals. It was known nanometer ... no one had been able to study its structure ... groundwater. Scientists at the U.S. Department of ...
... Spanish flu outbreak of 1918 killed between 30 and ... cause of death was acute respiratory distress syndrome (ARDS). ... body during which the lung becomes severely damaged. ARDS ... but also by chemical agents. These could be toxic ...
... the most common cause of episodic headache, and by ... visit. It affects some 15% of the population, including ... considerable burden on healthcare in both the developed and ... years, great strides have been made in discovering common ...
Cached Biology News:Scientists discover how nanocluster contaminants increase risk of spreading 2New strategies against bird flu 2Concentrating on different aspects of pain leads to breakthrough in migraine genetics 2
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... (g/L):,Tryptone, 10 ,Yeast extract, 5 ,Sodium ... ,Ferric ammonium citrate, 0.5 ,IPTG, 0.03 ... soluble, autoclavable chromogenic substrate for -galactosidase. ... -galactosidase generates a black insoluble precipitate. ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: